title: Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
abstract: OBJECTIVE
  To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity.
  
  
  METHODS
  Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to evaluate the antitumor efficiency of the vaccine. Immunohistochemistry, flow cytometric, and cytotoxic T-lymphocyte assay were performed to assess the proportion and cytotoxicity of the T lymphocytes.
  
  
  RESULTS
  The IL-2 surface-modified MB49 cell vaccine inhibited tumor growth and extended the survival of the mice, and the vaccine-cured mice effectively resisted the second MB49 but not the RM-1 prostate cancer cell challenge. Furthermore, more cytotoxicity on the MB49 cells and more CD4-positive, CD8-positive T cells appeared in the vaccine-treated group.
  
  
  CONCLUSIONS
  The results of our study have demonstrated that the human interleukin-2 surface-modified MB49 bladder cancer cell vaccine induced specific antitumor immunity and was efficient against metastatic bladder cancer.
authors: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors: Xinji
authors: X
authors: Zhang
authors: Xiaojun
authors: X
authors: Shi
authors: Jinlong
authors: J
authors: Li
authors: Zhiming
authors: Z
authors: Hu
authors: Fangfang
authors: F
authors: Guo
authors: Xiao
authors: X
authors: Huang
authors: Zhehuan
authors: Z
authors: Zhang
authors: Pengyu
authors: P
authors: Sun
authors: Yuming
authors: Y
authors: Jing
authors: Jimin
authors: J
authors: Gao
authors: Wanlong
authors: W
authors: Tan
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D011993:Recombinant Fusion Proteins; D019809:Streptavidin; D013601:T-Lymphocytes / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D019809:Streptavidin